More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings (-30.4% Growth)
- Ratings (4.1 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/29/16 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements
Licensing and royalty revenue
Total revenue 110.93M
Research and development
General and administrative 10.19M
Total operating expenses 94.82M
Loss from operations 16.11M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
Investment income 989K
Interest expense -9.75M
Gain (loss) on investments, net
Loss before income tax expense
Income tax expense 0
Net loss 7.35M
Basic net loss (in dollars per share) 0.06
Diluted net loss (in dollars per share) 0.06
Shares used in computing basic net loss per share (in shares) 120.99M
Shares used in computing diluted net loss per share (in shares) 123.38M